Table 2.
Baseline characteristics of the study cohort, as a group and according to anti-Ro52/TRIM21 antibody status
| Whole group (N = 963) |
Anti-Ro52/TRIM21 antibody positive (n = 194) | Anti-Ro52/TRIM21 antibody negative (n = 769) | Odds ratio (95% CI) and P values (Anti-Ro52/TRIM21 positive vs negative) | |||||
|---|---|---|---|---|---|---|---|---|
| Mean or n | SD or % | Mean or n | SD or % | Mean or n | SD or % | |||
| Age, years | 55.42 | 12.04 | 57.16 | 11.45 | 54.98 | 12.16 | 1.02 (1.00, 1.03) | 0.0481 |
| Female, % | 833 | 86.50% | 175 | 90.21% | 658 | 85.57% | NS | |
| White, % | 816 | 84.74% | 160 | 82.47% | 656 | 85.31% | NS | |
| Disease duration, years | 11.04 | 9.47 | 11.29 | 9.55 | 10.98 | 9.46 | NS | |
| Disease subsets, % | NS | |||||||
| Limited disease | 563 | 59.26% | 121 | 62.69% | 442 | 58.39% | ||
| Diffuse disease | 356 | 37.47% | 69 | 35.75% | 287 | 37.91% | ||
| Sine scleroderma | 31 | 3.26% | 3 | 1.55% | 28 | 3.70% | ||
| Modified Rodnan skin score (range, 0-51) | 10.02 | 9.47 | 9.68 | 8.53 | 10.11 | 9.69 | NS | |
| Swollen-joint count (range, 0-28) |
0.91 | 3.34 | 1.07 | 4.26 | 0.87 | 3.07 | NS | |
| Number of GI symptoms (range 0-14) | 4.17 | 3.13 | 4.27 | 3.30 | 4.14 | 3.09 | NS | |
| Inflammatory myositis, % | 103 | 11.48% | 21 | 11.54% | 82 | 11.47% | NS | |
| Thrombosis, % | 29 | 3.06% | 7 | 3.65% | 22 | 2.91% | NS | |
| Scleroderma renal crisis, % | 42 | 4.44% | 7 | 3.65% | 35 | 4.64% | NS | |
| Interstitial lung disease, % | 342 | 36.19% | 85 | 44.27% | 257 | 34.13% | 1.53 (1.11, 2.12) | 0.0091 |
| Pulmonary hypertension,% | 96 | 11.72% | 26 | 15.38% | 70 | 10.77% | NS | |
| Overlap with SLE, % | 30 | 3.19% | 8 | 4.23% | 22 | 2.93% | NS | |
| Overlap with Sjögren, % | 63 | 6.70% | 18 | 9.52% | 45 | 5.98% | NS | |
| Overlap with RA, % | 30 | 3.19% | 8 | 4.23% | 22 | 2.93% | NS | |
| Overlap with MCTD, % | 20 | 2.13% | 7 | 3.70% | 13 | 1.73% | NS | |
| Overlap with PM/DM, % | 36 | 3.83% | 12 | 6.35% | 24 | 3.19% | 2.06 (1.01, 4.19) | 0.0431 |
| Overlap syndrome, % | 143 | 15.18% | 41 | 21.58% | 102 | 13.56% | 1.75 (1.17, 2.63) | 0.0059 |
CI, confidence interval; GI, gastrointestinal; MCTD, mixed connective tissue disease; NS, not significant; overlap syndrome, overlap with systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, mixed connective tissue disease, and/or polymyositis/dermatomyositis; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus.